JP2003514030A5 - - Google Patents

Download PDF

Info

Publication number
JP2003514030A5
JP2003514030A5 JP2001537983A JP2001537983A JP2003514030A5 JP 2003514030 A5 JP2003514030 A5 JP 2003514030A5 JP 2001537983 A JP2001537983 A JP 2001537983A JP 2001537983 A JP2001537983 A JP 2001537983A JP 2003514030 A5 JP2003514030 A5 JP 2003514030A5
Authority
JP
Japan
Prior art keywords
composition
antigen
escherichia coli
mucoadhesive
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001537983A
Other languages
English (en)
Japanese (ja)
Other versions
JP4889175B2 (ja
JP2003514030A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/041241 external-priority patent/WO2001035993A2/en
Publication of JP2003514030A publication Critical patent/JP2003514030A/ja
Publication of JP2003514030A5 publication Critical patent/JP2003514030A5/ja
Application granted granted Critical
Publication of JP4889175B2 publication Critical patent/JP4889175B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001537983A 1999-10-18 2000-10-18 感染性因子に対する免疫応答を刺激するための組成物および方法 Expired - Fee Related JP4889175B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16002899P 1999-10-18 1999-10-18
US60/160,028 1999-10-18
PCT/US2000/041241 WO2001035993A2 (en) 1999-10-18 2000-10-18 Compositions and methods for stimulating an immune response against infectious agents

Publications (3)

Publication Number Publication Date
JP2003514030A JP2003514030A (ja) 2003-04-15
JP2003514030A5 true JP2003514030A5 (https=) 2007-11-22
JP4889175B2 JP4889175B2 (ja) 2012-03-07

Family

ID=22575185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001537983A Expired - Fee Related JP4889175B2 (ja) 1999-10-18 2000-10-18 感染性因子に対する免疫応答を刺激するための組成物および方法

Country Status (6)

Country Link
US (2) US20090130141A1 (https=)
EP (1) EP1221970B1 (https=)
JP (1) JP4889175B2 (https=)
CA (1) CA2388054C (https=)
ES (1) ES2462532T3 (https=)
WO (1) WO2001035993A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413523B1 (en) * 1989-06-02 2002-07-02 The United States Of America As Represented By The Secretary Of The Navy Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5985243A (en) * 1994-09-28 1999-11-16 Chiron S.P.A. Mouse model for Helicobacter pylori infection
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP0919243A1 (en) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant

Similar Documents

Publication Publication Date Title
Almeida et al. Nasal delivery of vaccines
Vajdy et al. Microparticles for intranasal immunization
Holmgren et al. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges
Chen Recent advances in mucosal vaccine development
WO2000047222A3 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
HUP0100058A1 (hu) LTB Adjuvánst tartalmazó vakcinák
Plante et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge
JP2001523729A5 (https=)
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
DE69921773D1 (de) Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe
BR9509190A (pt) Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano
US20100008951A1 (en) Flu vaccine admixture of mannan and flu antigen
US20100330183A1 (en) Solid dispersing vaccine composition for oral delivery
EP1024824A1 (en) Solid dispersing vaccine composition for oral delivery
PT1015595E (pt) Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio
JP2003514030A5 (https=)
NO951982D0 (no) Mucosal tilförsel av pneumokokkiske antigener
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
JP2003510292A5 (https=)
Corrigan et al. Is there a role for a mucosal influenza vaccine in the elderly?
Clancy Mucosal vaccines for the prevention of influenza
WO2003050135A3 (en) Use a parapox b2l protein to modify immune responses to administered antigens
PT721782E (pt) Vacina contra a gripe contendo toxina da tosse convulsa